Ferrostatin-1 suppresses cardiomyocyte ferroptosis after myocardial infarction by activating Nrf2 signaling
Journal of Pharmacy and Pharmacology · 2023
DOI: 10.1093/jpp/rgad080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2023. Verfasst von Yu-Ting Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Binzhou Medical University Hospital, Binzhou 256603, China. Hauptthemen laut MEDLINE: Ferroptosis, Myocardial Infarction. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, GuangDong Basic and Applied Basic Research Foundation, Chinese Postdoctoral Science Foundation.
Abstract (Originalsprache)
Objectives
Ferroptosis, a new regulated cell death pathway, plays a crucial part in the development of cardiovascular disease. However, the precise underlying mechanism remains unclear. Therefore, this study aimed to elucidate this.
Methods
Herein, an erastin-induced H9C2 cell ferroptosis in vitro model and a myocardial infarction murine model, which was created by ligating the left anterior descending coronary artery, were established. Ferroptosis-related indicators, myocardial injury-related indicators, and Nrf2 signaling-related proteins expression were analyzed to explore the potential mechanism underlying cardiomyocyte ferroptosis-mediated cardiovascular disease development.
Results
We demonstrated that Nrf2 downregulation in myocardial tissue, accompanied by ferroptotic events and changes in xCT and GPX4 expressions, induced cardiomyocyte ferroptosis and myocardial injury after myocardial infarction. These events, including ferroptosis and changes in Nrf2, xCT, and GPX4 expressions, were improved by ferrostatin-1 in vivo and in vitro. Besides, Nrf2 deficiency or inhibition aggravated myocardial infarction-induced cardiomyocyte ferroptosis by decreasing xCT and GPX4 expressions in vivo and in vitro. Moreover, ferrostatin-1 directly targeted Nrf2, as evidenced by surface plasmon resonance analysis.
Conclusions
These results indicated that myocardial infarction is accompanied by cardiomyocyte ferroptosis and that Nrf2 signaling plays a crucial part in regulating cardiomyocyte ferroptosis after myocardial infarction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Binzhou Medical University Hospital, Binzhou 256603, China.
- School of Traditional Chinese Medicine, Department of Traditional Chinese Medicine, Nanfang Hospital (ZengCheng Branch), Southern Medical University, Guangzhou 510515, China.
- Department of Traditional Chinese Medicine, Yangjiang People's Hospital, Yangjiang 529500, China.
- Guangzhou Institute of Cardiovascular Disease, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
- Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510000, China.
ORCID-Profile: Ying-Chun Zhou
Förderung
- National Natural Science Foundation of China
- GuangDong Basic and Applied Basic Research Foundation
- Chinese Postdoctoral Science Foundation
- Guangdong Provincial Enterprise Joint Fund
Zitieren
APA
Wu, Y. T., Zhang, G. Y., Hua, Y., Fan, H. J., Han, X., Xu, H. L., Chen, G. H., Liu, B., Xie, L. P., & Zhou, Y. C. (2023). Ferrostatin-1 suppresses cardiomyocyte ferroptosis after myocardial infarction by activating Nrf2 signaling. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgad080
Vancouver
Wu YT, Zhang GY, Hua Y, Fan HJ, Han X, Xu HL, et al. Ferrostatin-1 suppresses cardiomyocyte ferroptosis after myocardial infarction by activating Nrf2 signaling. Journal of Pharmacy and Pharmacology. 2023. doi:10.1093/jpp/rgad080
BibTeX
@article{Wu2023,
author = {Wu, Yu-Ting and Zhang, Guo-Yong and Hua, Yue and Fan, Hui-Jie and Han, Xin and Xu, Hong-Lin and Chen, Guang-Hong and Liu, Bin and Xie, Ling-Peng and Zhou, Ying-Chun},
title = {Ferrostatin-1 suppresses cardiomyocyte ferroptosis after myocardial infarction by activating Nrf2 signaling},
journal = {Journal of Pharmacy and Pharmacology},
year = {2023},
doi = {10.1093/jpp/rgad080}
}
EUVIMED